OpenAlex
PricingAboutJobs
Log inGet started
Work

The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents

HTML

Year: 2017
Type: article
Source: Blood
DOI: 10.1182/blood-2017-10-809293
Authors: Maria Gavriatopoulou, Efstathios Kastritis, Ioannis Ntanasis-Stathopoulos, Despina Fotiou, Maria Roussou, Magdalini Migkou, Dimitrios C. Ziogas, Nikolaos Kanellias, Evangelos Terpos, Meletios Athanasios Dimopoulos
Institution: National and Kapodistrian University of Athens
Language: English

Topic: Multiple Myeloma Research and Treatments
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Keywords: daratumumab, multiple myeloma, refractory multiple myeloma, immunomodulators, lenalidomide, pomalidomide, combination therapy, treatment refractoriness
SDG: Good health and well-being

Open Access status: closed
OpenAlex ID: W2768845394
FWCI: 5.241
Cites: 24
Cited by: 61
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms
Security